Corbus Pharmaceuticals (NASDAQ: CRBP) announced Monday September 14, 2026 positive topline results from the Phase 1b CANYON-1 trial evaluating CRB-913 (once-daily oral peripherally-restricted CB1 inverse agonist for obesity) in 254 obese non-diabetic U.S. adults across 15 sites (NCT07310901). Mean weight loss at 12 weeks: 5.0% at 60 mg (n=62), 3.3% at 40 mg (n=61), 2.8% at 20 mg (n=65) versus 0.0% on placebo (n=66) — all p<0.0001. No plateau was observed at any dose. Discontinuation rates ranged 3.1-13.1% across doses (comparable to 6.9-20.7% for oral GLP-1s in cross-trial comparison). At the 60 mg dose: nausea 22.6%, diarrhea 22.6%, constipation 4.8%, vomiting 1.6%. Psychiatric adverse events at 60 mg: depression 1.6%, anxiety 4.8%, irritability 9.7%, insomnia 0% — no serious psychiatric events or suicidality reported. CRB-913 was designed with approximately 15-fold lower brain penetration than monlunabant in preclinical models to preserve CB1-driven weight loss while limiting the psychiatric side effects that led to the 2008 withdrawal of Sanofi's Acomplia (rimonabant). CRBP shares closed up 12% on the day. Next steps: FDA clinical development plan engagement, Phase 2 monotherapy trial initiation in H1 2027, evaluation of a GLP-1 combination approach, and full data presentation at ObesityWeek 2026 (November 14-17, Washington DC).
Novo Nordisk (NYSE: NVO; Copenhagen: NOVO-B) shares closed at DKK 298.95 in Copenhagen on Monday September 7, 2026 (roughly 1.9% below Friday) after the company's simultaneous release of STEP Young Phase 3 pediatric semaglutide data (40.4% of children aged 6 to under 12 achieved BMI below the obesity threshold at week 68 versus 0% placebo) and confirmation that the HERMES and ATHENA Phase 3 ziltivekimab (anti-IL-6 monoclonal antibody) heart-failure trials had been terminated early after a data monitoring committee ruled the studies unlikely to succeed. Barclays' James Gordon cut the Novo Nordisk price target from DKK 310 to DKK 300 while maintaining an Equal Weight rating. Analyst commentary broadly framed the day as a scientific-engine-versus-diversification tension: the semaglutide franchise continues to add indication paths (pediatric obesity below 12 years is one of the last major label extensions available), while the non-GLP-1 diversification story tied to ziltivekimab now depends primarily on the post-acute heart-failure study that remains ongoing. Detailed STEP Young results will be presented at ObesityWeek 2026 in Washington DC November 14-17.
Novo Nordisk (NYSE: NVO) announced Monday September 7, 2026 first results from STEP Young, a Phase 3 randomized double-blind placebo-controlled multinational trial evaluating once-weekly semaglutide combined with a reduced-calorie diet and increased physical activity in children aged 6 to under 12 years with obesity. The trial enrolled 165 children, dosed with a maximum of 1.7 mg or 2.4 mg semaglutide based on baseline weight. At week 68, 40.4% of the semaglutide group had a BMI below the obesity threshold versus 0% in the placebo group; more than 85% of enrolled children had class II or III severe obesity (BMI ≥35 or ≥40 by adult equivalents) at baseline. Safety and tolerability were consistent with adult and adolescent trials with no new safety concerns and no signals related to growth or pubertal development. Detailed results will be presented at ObesityWeek 2026 in Washington DC November 14-17. Wegovy is currently approved in the U.S. for adolescents 12 and older; a supplemental submission for children under 12 has not been announced.